Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of two mipomersen dosing regimens in severe familial hypercholesterolemia
NL-OMON39591Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mipomersen in familial hypercholesterolemia (FH) (3 arms), sponsored by Sanofi. Primary endpoint: Percent change in LDL-C in cohort 1. Started Nov 2011; status: active, not recruiting.
02
Drugs
mipomersen
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON39591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39591.